ELOX
Eloxx Pharmaceuticals, Inc.
Set alert
- YTD
- +22.16%
- 1 year
- +22.16%
- Open
- 13.35
- Prev close
- 13.18
- Mkt cap
- 54.29M
- Vol
- 13.99K
- Avg vol
- 34.36K
- EPS
- 3.52
- P/E
- 3.82
- Div yield
- 0.00%
More statistics
- Low
- 12.99
- High
- 13.77
- Forward P/E
- -0.87
- Beta
- 2.61
- Short ratio
- 0.63
- Inst. own
- 43.97%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 23, 2024
- 50-d avg
- 6.06
- 200-d avg
- 5.01
- 1y target
- 55.00
News
1 day ago prnewswire.com
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
FDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKD EXPRESS will randomize approximately 60 patients 1:1 to…
-
2 days ago benzinga.com
Guggenheim Maintains Buy on Eloxx Pharma, Lowers Price Target to $40
Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.
-
1 week ago benzinga.com
Eloxx Pharmaceuticals Finalizes Design For Its EXPRESS Phase 2 Global Trial In Nonsense-Mutation Autosomal Dominant Polycystic Kidney Disease To Enrolol 60 Adults With Genetically Confirmed PKD1 Or PKD2 Nonsense Mutations
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced the finalized design of its…
1 week ago prnewswire.com
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D.
EXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to ex aluren or placebo, with annualized htTKV growth as the primary endpoint Substantial, durable…
1 week ago prnewswire.com
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
Mr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical business Extensive public company board…
2 weeks ago benzinga.com
This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
2 weeks ago benzinga.com
This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Neutral on RDW, Overweight on ELOX, Buys on SGHT and AU, and Market Perform on FFIN.
-
2 weeks ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Overweight rating.
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY)…
1 month ago defenseworld.net
Head to Head Comparison: Eloxx Pharmaceuticals (NASDAQ:ELOX) & LENZ Therapeutics (NASDAQ:LENZ)
LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) and Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
-
1 month ago benzinga.com
Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.
1 month ago prnewswire.com
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON,…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million. Jupiter Neurosciences…
-
2 months ago benzinga.com
LUCID CAPITAL MARKETS Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $38
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $38.
2 months ago prnewswire.com
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial…
-
3 months ago benzinga.com
LifeSci Capital Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $40
LifeSci Capital analyst Rami Katkhuda initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $40.
-
3 months ago benzinga.com
Guggenheim Initiates Coverage On Eloxx Pharma with Buy Rating, Announces Price Target of $43
Guggenheim analyst Vamil Divan initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Buy rating and announces Price Target of $43.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ:RGC) stock moved…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
4 months ago prnewswire.com
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule…
9 months ago defenseworld.net
Contrasting Eloxx Pharmaceuticals (NASDAQ:ELOX) & Prime Medicine (NYSE:PRME)
Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) and Prime Medicine (NYSE: PRME - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two…
9 months ago defenseworld.net
Contrasting Finch Therapeutics Group (NASDAQ:FNCH) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch…
9 months ago defenseworld.net
Critical Contrast: Eloxx Pharmaceuticals (NASDAQ:ELOX) & Finch Therapeutics Group (NASDAQ:FNCH)
Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of…
10 months ago defenseworld.net
Critical Contrast: Cortexyme (NASDAQ:CRTX) vs. Eloxx Pharmaceuticals (NASDAQ:ELOX)
Valuation and Earnings This table compares Eloxx Pharmaceuticals and Cortexyme"s top-line revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per…
10 months ago defenseworld.net
Cortexyme (NASDAQ:CRTX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Critical Contrast
Insider and Institutional Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of…
11 months ago defenseworld.net
Cortexyme (NASDAQ:CRTX) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Survey
Institutional and Insider Ownership 2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 20.2% of…
2 years ago globenewswire.com
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations
2 years ago globenewswire.com
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
ELX-02 Granted Orphan Drug Designation (ODD) from U.S. Food and Drug Administration (FDA) for Treatment of Alport Syndrome
2 years ago globenewswire.com
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
BARCELONA, Spain and WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an…
2 years ago businesswire.com
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
BARCELONA, Spain & WATERTOWN, Mass.--(BUSINESS WIRE)--Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license…
2 years ago investorplace.com
Off the Beaten Path: 3 Delisted Stocks for The Speculative Investor
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically,…
2 years ago globenewswire.com
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update
Kidney morphology improved in all three patients with protein re-expression consistent with disease regression in its Phase 2 open-label clinical trial of ELX-02 for the treatment of Alport Syndrome
-
3 years ago benzinga.com
Why 22nd Century Group Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shares jumped 283.7% to $1.3007 after Harmony Biosciences entered into definitive agreement to acquire the company for total potential…
-
3 years ago benzinga.com
Why Progressive Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers
-
3 years ago benzinga.com
Why Senmiao Technology Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Gainers Jiuzi Holdings, Inc. (NASDAQ: JZXN) shares surged 106.8% to $5.77 in pre-market trading. The stock began trading on a 1:18 reverse split on July 10.
-
3 years ago benzinga.com
Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket
Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.
-
3 years ago benzinga.com
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering.
-
3 years ago benzinga.com
Dow Tumbles Over 200 Points; US Retail Sales Rise In April
U.S. stocks traded lower this morning, with the Dow Jones dropping over 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.71% to 33,111.92 while the NASDAQ fell 0.10%…
-
3 years ago benzinga.com
Why Tupperware Brands Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers PLx Pharma Inc. (NASDAQ: PLXP) gained 128.2% to $0.2399 after dropping over 13% on Thursday.
-
3 years ago benzinga.com
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 329 companies set new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 115 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 72 companies hit new 52-week lows.
-
3 years ago benzinga.com
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250.
-
4 years ago benzinga.com
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
-
4 years ago benzinga.com
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day…